MORE BENEFITS WITH NEW STRATEGIES IN HORMONAL CONTRACEPTION
G. Grandi, A. Cagnacci, A. Volpe

Established benefits of combined hormonal contraception include ovarian, endometrial and colorectal cancer prevention and effective treatment for endometriosis-related pain, acne/hirsutism, hypermenorrhea, dysmenorrhea and premenstrual symptoms.

New strategies in hormonal contraception include use of estradiol, of particular progestins, of extended/continuous regimens and of non-oral ways of administration.

In comparison to traditional ethinyl-estradiol, estradiol (estradiol valerate, micronized estradiol) guarantees a minor hepatic impact, with a neutral balance on lipids and glucose metabolism and coagulation. This effect should be connected with a reduced risk of thrombotic events, though not yet confirmed by large epidemiological data.

The new progestins (DNG, DRSP, CMA, NOMAC) associate an anti-androgenic potency with specific therapeutic effects (for example high endometrial tropism for DNG, anti-mineralocorticoid for DRSP etc).

Continuous regimens of combined contraceptives protect against menstrual flow related problems like headache, menstrual pain and menorrhagia. These regimens seems more effective in endometrioma-relapse prevention.

Different ways of administration (intra-uterine, intra-vaginal, transdermal, subdermal, injectable) facilitate compliance of users, with a minor risk of forgetfulness and related contraceptive failure.

LNG-IUS can be used for meno-metrorrhagia also fibroid-related treatment and pain-relief in isolated deep infiltrating endometriosis/adenomyosis.